May 17, 2022 8:00am EDT Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
Jan 27, 2022 7:30am EST Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Sep 15, 2021 8:00am EDT Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
Aug 26, 2021 8:00am EDT Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
Jul 29, 2021 8:00am EDT Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
May 27, 2021 8:00am EDT Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
May 24, 2021 8:00am EDT Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing
May 05, 2021 8:00am EDT Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board
May 03, 2021 8:00am EDT Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer